Alexion’s new CEO is bringing an old colleague in to run R&D, can new deals be far behind?
After announcing a clean sweep of the executive suite a few days ago, Alexion’s new CEO Ludwig Hantson is bringing in a very familiar face to take over as head of R&D.
Hantson chose John Orloff, his R&D chief at the short-lived Baxalta, to take over the helm at Alexion’s research group, replacing Martin Mackay. The move likely signals some looming pipeline changes at the company, which sells Soliris, one of the world’s most expensive therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.